Analyst Ratings Network logo

NASDAQ:ESTA - Establishment Labs Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $31.75
  • Forecasted Upside: -34.02 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$48.12 As of 01/20/2021 01:00 AM ET
▼ -3.48 (-6.74%)
1 month | 3 months | 12 months
Get New Establishment Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ESTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ESTA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$31.75
▼ -34.02% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Establishment Labs in the last 3 months. The average price target is $31.75, with a high forecast of $61.00 and a low forecast of $20.00. The average price target represents a -34.02% upside from the last price of $48.12.
Buy
The current consensus among 4 investment analysts is to buy stock in Establishment Labs. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/13/2021BTIG ResearchBoost Price TargetBuy$41.00 ➝ $61.00High
i
9/21/2020BTIG ResearchReiterated RatingBuyHigh
i
Rating by Marie Thibault at BTIG Research
8/27/2020UBS GroupInitiated CoverageBuy$23.00Medium
i
8/7/2020BTIG ResearchReiterated RatingBuy$33.00High
i
Rating by Marie Thibault at BTIG Research
5/14/2020The Goldman Sachs GroupInitiated CoverageNeutral$20.00Medium
i
5/7/2020BTIG ResearchReiterated RatingBuy$35.00Medium
i
Rating by Marie Thibault at BTIG Research
3/23/2020StephensLower Price TargetOverweight$30.00 ➝ $23.00Low
i
3/17/2020BTIG ResearchLower Price TargetBuy$40.00 ➝ $35.00High
i
Rating by Marie Thibault at BTIG Research
2/5/2020BTIG ResearchInitiated CoverageBuy$40.00Low
i
Rating by Marie Thibault at BTIG Research
7/12/2019Wells Fargo & CompanySet Price TargetBuy$29.00Low
i
Rating by David Maris at Wells Fargo & Company
6/28/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$29.00High
i
6/6/2019StephensInitiated CoverageOverweight$37.00Medium
i
5/16/2019BTIG ResearchReiterated RatingBuy$40.00Low
i
3/25/2019BTIG ResearchReiterated RatingBuy$40.00Medium
i
11/14/2018BTIG ResearchBoost Price TargetBuy$40.00Medium
i
8/13/2018BTIG ResearchInitiated CoverageBuy$35.00High
i
8/13/2018CowenInitiated CoverageOutperform$35.00High
i
8/13/2018Jefferies Financial GroupInitiated CoverageBuy$35.00High
i
(Data available from 1/20/2016 forward)
Establishment Labs logo
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in 80 countries worldwide. Establishment Labs Holdings Inc. was founded in 2004 and is headquartered in Alajuela, Costa Rica.
Read More

Today's Range

Now: $48.12
$48.10
$53.14

50 Day Range

MA: $36.77
$27.77
$51.60

52 Week Range

Now: $48.12
$7.56
$54.97

Volume

94,126 shs

Average Volume

131,619 shs

Market Capitalization

$1.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15

Frequently Asked Questions

What sell-side analysts currently cover shares of Establishment Labs?

The following sell-side analysts have issued research reports on Establishment Labs in the last year: BTIG Research, Stephens, The Goldman Sachs Group, Inc., UBS Group AG, and Zacks Investment Research.

What is the current price target for Establishment Labs?

4 Wall Street analysts have set twelve-month price targets for Establishment Labs in the last year. Their average twelve-month price target is $31.75, suggesting a possible downside of 37.4%. BTIG Research has the highest price target set, predicting ESTA will reach $61.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $20.00 for Establishment Labs in the next year.

What is the current consensus analyst rating for Establishment Labs?

Establishment Labs currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ESTA will outperform the market and that investors should add to their positions of Establishment Labs.

What other companies compete with Establishment Labs?

Other companies that are similar to Establishment Labs include Avanos Medical, Eargo, Inogen, Invacare, Sanara MedTech, Sientra, Lakeland Industries, Histogenics, United Health Products, Alpha Pro Tech, Surgalign, Milestone Scientific, Conformis, Nutriband and CollPlant Biotechnologies.

How do I contact Establishment Labs' investor relations team?

Establishment Labs' physical mailing address is Building B15 and 25 Coyol Free Zone, Alajuela G2, . The company's listed phone number is 506 2434 2400 and its investor relations email address is ir@establishmentlabs.com. The official website for Establishment Labs is www.establishmentlabs.com.